biotech / news / / MarketScreener
Astellas Pharma Inc. announced the first results from the open-label extension trial of the Phase 3 GATHER2 study.
IZERVAY continued to reduce GA lesion growth for up to 3.5 years in treated patients.
KEY POINTS
- Earlier initiation of IZERVAY treatment showed greater retinal tissue protection in GA patients.
- No cases of retinal vasculitis or occlusive vasculitis were reported during the long-term extension trial.
- Real-world U.S. data confirmed low discontinuation rates and no new safety signals for IZERVAY.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →